Dishman Carbogen Amcis Limited (DCAL) announced its un-audited financial results for the third quarter and nine months ended December 31, 2025, following a Board of Directors meeting held on February 3, 2026. The company reported a consolidated net loss of ₹12.97 crore for the third quarter, a significant shift from a profit of ₹4.63 crore in the same period last year. Total income from operations for the quarter stood at ₹719.80 crore, an increase from ₹682.34 crore in the prior year's third quarter. The nine-month period ended December 31, 2025, also showed a consolidated net profit of ₹65.27 crore, compared to a loss of ₹39.85 crore in the corresponding period of the previous year. For the standalone results, the company registered a net loss of ₹23.13 crore for the third quarter ended December 31, 2025, an increase from a loss of ₹13.28 crore in the third quarter of the previous year. The nine-month standalone period ended December 31, 2025, reported a net loss of ₹34.06 crore, compared to a loss of ₹2.50 crore in the same period last year. The company also provided additional information regarding its financial ratios and debt-equity position, noting a debt-equity ratio of 0.43 for the consolidated results and 0.17 for standalone results as of December 31, 2025. A detailed note on the accounting treatment of goodwill arising from the amalgamation of Dishman Pharmaceuticals and Chemical Limited and Dishman Care Limited was also provided, with the Board deciding to amortize the goodwill over 99 years from January 1, 2015, prospectively from April 1, 2024.
